OakChart

Intensity Therapeutics Inc

INTSHealthcare·Biotechnology·USA·Nano·NASD·Nov 12 • 3:59 PM ET

3.10-0.18 (-5.49%)
2026-11-13 06:52 CET
Market cap
$10.24M
Revenue, TTM
0.00 USD m
Net income, TTM
-12.04 USD m
Free cash flow, TTM
-9.07 USD m
EPS diluted, TTM
-4.37
Price / earnings
-
Compare

Price

INTS against its 20, 50 and 200-day averages
Terms2050200BeatEarnings
Patternshover a marker to name it
RS 0Sales 0.00Price0.004.006.008.0087K173KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26INTSclose 3.1020-day 3.2550-day 3.55200-day 4.923.1052w low 2.8052-week range, not 6 months

79.3% under the 52-week high of 15.00 on 11 Dec 2025. 52-week low 2.80 on 5 Nov 2026. Last 15 sessions, 27.7% high to low

Volume 0.47× normal · the line is the 50-bar volume average

Setup. RS line 0
CANSLIM 2 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%; Average Volume: Over 200K
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 0 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 3 of 4 — fails: Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15% — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 2 of 4 — fails: Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Average Volume: Over 500K; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 0 of 4 — fails: Institutional Ownership: Over 30%; Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 0 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200; Average Volume: Over 500K

Profile

INTS
52-week range, 2% of the way up
2.8015.00

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.

Employees16
IPOJun 30, 2023
Beta3.04
ATR, 14d0.31
Rel volume0.47
Short float2.39%
Insider own3.92%
Inst own25.74%

Snapshot

6 groups

Valuation

Index-
Market Cap$10.24M
Enterprise Value1.84M
Income-12.04M
Sales0.00M
Book / share2.32
Cash / share2.57
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees16
IPOJun 30, 2023

Ratios

Price / earnings-
Forward price / earnings-
Price / earnings / growth-
Price / sales-
Price / book1.34
Price / cash1.21
Price / free cash flow-
Value / cash profit-
Value / sales-
Quick Ratio3.68
Current Ratio3.68
Debt / equity0.01
Long-term debt / equity0.01
Options and shortNo / Yes

Earnings

Earnings / share-4.37
Earnings next year-2.56
Earnings next quarter-1.06
Earnings this year50.63%
Earnings next year39.54%
Earnings growth, 5 years26.38%
Past earnings growth16.06% 5.76%
Past sales growth- -
Earnings vs last year72.47%
Sales vs last year-
Earnings vs last quarter29.85%
Sales vs last quarter-
EarningsNov 05 BMO
Surprise-10.55% -

Ownership

Insiders own3.92%
Insider trades0.00%
Institutions own25.74%
Institution trades7.20%
Return on assets-121.14%
Return on equity-161.84%
Return on capital-156.21%
Gross Margin-
Operating margin-
Profit Margin-
20-day average-4.66%
50-day average-12.71%
200-day average-37.00%

Technical

Shares out3.30M
Shares floating3.17M
Short / float2.39%
Short ratio3.24
Short interest0.08M
52-week high15.00 -79.3%
52-week low2.80 +10.7%
Volatility10.03% 8.55%
Average range0.31
Strength index42.36
Market sensitivity3.04
Relative volume0.47
Avg Volume23.43K
Volume11,080

Performance

Perf Week0.00%
Perf Month-9.36%
Perf Quarter-21.72%
Perf Half Y-36.73%
Perf YTD-69.77%
Perf Year-75.78%
Perf 3Y-95.44%
Perf 5Y-
Perf 10Y-
Recommendation1.00
Target Price16.40
Prev Close3.28
Price3.10
Change %-5.49%

Peers

Mkt cap
TickerCompanyMkt cap
IMNNImunon Inc3.57M
PHIOPhio Pharmaceuticals Corp9.70M
CADLCandel Therapeutics Inc641.99M
REPLReplimune Group Inc2.08B
VRCAVerrica Pharmaceuticals Inc63.91M
HURATuHURA Biosciences Inc92.40M
CLDICalidi Biotherapeutics Inc2.41M
ONCYOncolytics Biotech Inc47.43M
TOVXTheriva Biologics Inc7.34M
BCTXBriaCell Therapeutics Corp30.64M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.79B

News

latest 14 of 168
  • Intensity Therapeutics Misses As Trial Restarts Lift Spending; Cash, Not Data, Sets The Pace For INVINCIBLE-3 (Earnings Whispers) -11.43%
  • Intensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
  • Intensity Therapeutics Heads Into Q3 With Cash Runway And Trial Restarts Under Scrutiny (Earnings Whispers)
  • Intensity Therapeutics to Announce Third Quarter 2026 Financial Results on November 5, 2026 (PR Newswire)
  • Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting (PR Newswire)
  • Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire)
  • Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
  • Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026 (PR Newswire)
  • Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) (PR Newswire)
  • Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 (PR Newswire)
  • Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award (PR Newswire)
  • Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
  • Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation (PR Newswire)
  • Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update (PR Newswire) -5.80%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-1.090-0.986-0.9900.000.005
2026Q22026-08-11-1.110-0.873-1.1110.000.004
2026Q12026-05-07-0.960-1.085-0.9610.000.004
2025Q42026-03-271.690-1.240-1.2090.000.005
2025Q32025-11-06-1.500-1.583-1.5510.000.003
2025Q22025-08-07-3.250-4.250-3.3620.000.003
2025Q12025-05-13-5.500-5.000-5.5150.000.003
2024Q42025-03-13-5.500-5.600-5.4370.000.005
2024Q32024-11-13-6.250-7.625-6.3620.000.004
2024Q22024-08-08-9.000-8.000-9.0630.000.002
2024Q12024-05-09-8.5000.000-8.3940.000.001
2023Q42024-03-14-5.750-4.500-5.7840.000.001
2023Q32023-11-13-4.250-2.250-4.2490.000.001
2023Q22023-08-14-35.750-10.000-7.0630.000.001
2023Q12023-07-17-9.750--2.5510.00--
2026Q4---1.058--0.005

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-34.500-32.250-34.4170.000.00
2024FY-29.250-29.250-29.2440.000.00
2025FY-8.560-7.873-8.5600.000.00
2026FY--4.226--0.00
2027FY--2.555--0.00
2028FY--3.415--52.45
2029FY-3.230--112.05
2030FY-6.665--176.69

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-053000.000.000.00
2026Q4S2026-08-173000.000.000.00
2026Q4S2026-08-112000.000.000.00
2026Q4S2026-05-082000.000.000.00
2026Q4S2026-03-302000.000.000.00
2026Q4S2025-11-131000.000.000.00
2026Q4S2025-11-121000.000.000.00
2026Q4S2025-11-111000.000.000.00
2026Q4R2026-11-06101-0.91-0.91-0.91
2026Q4R2026-11-05100-0.87-0.87-0.87
2026Q4R2026-10-26100-0.87-0.87-0.87
2026Q4R2026-08-12110-0.87-0.87-0.87
2026Q4R2026-08-11100-1.13-1.13-1.13
2026Q4R2026-05-08100-1.13-1.13-1.13

Estimate history

EPS, annual-10.267-11.509-15.069-14.47-34.417-29.244-8.557-4.3681
Period2019202020212022202320242025TTM
EPS, quarterly-6.362-5.437-5.515-3.362-1.551-1.209-0.961-1.111-1.088
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00000000
Period2019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.5240.5240.5240.5240.5480.6052.5243.296
Period2019202020212022202320242025MRQ
Shares, quarterly0.5550.6050.6111.0471.9632.5242.5412.9463.296
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.030.030.030.150.180.000.000.00
Gross Profit-0.03-0.03-0.03-0.15-0.180.000.000.00
Selling, General and Administrative Excl. Other12.3511.9516.568.177.458.016.225.68
Research and Development6.966.7910.504.795.134.115.054.44
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-12.37-11.97-16.59-8.32-7.63-8.01-6.22-5.68
Interest Expense0.000.000.000.30--0.000.00
Unusual Expense0.000.000.002.260.000.000.000.00
Net Income Before Taxes-12.04-11.61-16.27-10.54-7.58-7.90-6.03-5.38
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-12.04-11.61-16.27-10.54-7.58-7.90-6.03-5.38
Net Income From Continuing Operations-12.04-11.61-16.27-10.54-7.58-7.90-6.03-5.38
Net Income-12.04-11.61-16.27-11.86-7.58-7.90-6.03-5.38
EPS (Recurring)-3.70-8.56-29.24-29.82-14.47-15.07-11.51-10.27
EPS (Basic, Before Extraordinaries)-4.37-8.56-29.24-34.42-14.47-15.07-11.51-10.27
EPS (Diluted)-4.37-8.56-29.24-34.42-14.47-15.07-11.51-10.27
EBITDA-12.35-11.95-16.56-8.17-7.45-8.01-6.22-5.68
Non-Operating Income (Expense)0.340.370.320.350.050.120.190.30
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.742.003.071.401.170.720.560.56
Shares Outstanding3.302.520.600.550.520.520.520.52
Market Capitalization10.2310.2326.62117.49117.49---

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.010.010.010.010.010.010.01
Gross Profit-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01
Selling, General and Administrative Excl. Other3.623.082.523.132.732.703.393.20
Research and Development2.431.831.201.501.551.542.191.97
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.62-3.08-2.53-3.14-2.73-2.71-3.39-3.20
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-3.54-3.01-2.43-3.05-2.67-2.54-3.35-3.18
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-3.54-3.01-2.43-3.05-2.67-2.54-3.35-3.18
Net Income From Continuing Operations-3.54-3.01-2.43-3.05-2.67-2.54-3.35-3.18
Net Income-3.54-3.01-2.43-3.05-2.67-2.54-3.35-3.18
EPS (Recurring)-1.09-1.11-0.96-1.21-1.55-3.36-5.51-5.44
EPS (Basic, Before Extraordinaries)-1.09-1.11-0.96-1.21-1.55-3.36-5.51-5.44
EPS (Diluted)-1.09-1.11-0.96-1.21-1.55-3.36-5.51-5.44
EBITDA-3.62-3.08-2.52-3.13-2.73-2.70-3.39-3.20
Non-Operating Income (Expense)0.080.080.090.090.060.170.050.02
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.520.390.390.450.470.640.430.84
Shares Outstanding3.302.952.542.521.961.050.610.60
Market Capitalization10.2311.0814.9425.8911.918.0330.0726.62

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments11.922.5914.781.314.549.328.39
Short Term Receivables0.000.000.000.060.050.070.03
Inventories0.000.000.000.000.000.000.00
Other Current Assets0.790.770.690.080.140.240.22
Total Current Assets12.713.3615.461.454.739.638.65
Net Property, Plant & Equipment0.100.120.150.140.320.490.25
Total Investments and Advances0.000.000.000.000.000.000.00
Long-Term Note Receivable----0.000.050.07
Intangible Assets0.000.000.000.00---
Deferred Tax Assets0.03------
Other Assets1.301.301.680.170.170.030.03
Total Assets14.134.7817.301.765.2210.209.01
Short Term Debt Incl. Current Port. of LT Debt0.030.030.024.492.200.170.12
Accounts Payable0.581.223.050.600.170.220.39
Other Current Liabilities1.530.510.891.721.350.950.62
Total Current Liabilities2.151.753.966.823.721.351.13
Long Term Debt0.080.110.140.000.140.330.14
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities0.03------
Other Liabilities0.000.000.040.040.040.040.04
Total Liabilities2.251.864.136.853.901.711.31
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.0010.0010.0010.0010.00
Common Equity11.882.9213.16-15.10-8.68-1.51-2.30
Total Shareholders Equity11.882.9213.16-5.101.328.497.70
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity11.882.9213.16-5.101.328.497.70
Total Liabilities & Stockholders Equity14.134.7817.301.765.2210.209.01
Book Value Per Share4.704.8224.00-28.81-16.57-2.88-4.39
Tangible Book Value Per Share4.704.8224.00-28.81-16.57-2.88-4.39
Full-Time Employees1616171622--
Price to Book Ratio1.349.127.387.38---
Return on Assets-122.75-147.37-110.62-217.46-102.43-62.80-
Return on Equity-156.90-202.34-261.33--161.01-74.49-
Return on Invested Capital-97.08-537.25-79.23--540.99-68.39-68.60
Quick Ratio5.921.923.910.211.277.157.67
Current Ratio5.921.923.910.211.277.157.67

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-12.04-11.61-16.27-10.54-7.58-7.90-6.03-5.38
Depreciation0.030.030.030.150.18---
Other Funds (Non Cash)1.742.003.123.821.170.890.670.66
Funds from Operations-10.27-9.58-13.12-6.57-6.23-7.00-5.36-4.72
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital1.200.35-2.10-0.630.760.18-0.010.31
Cash from Operating Activities-9.07-9.23-15.22-7.21-5.48-6.83-5.37-4.42
Capital Expenditures0.000.000.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.006.35-6.020.000.004.561.70
Purchase of Investments0.000.00-3.06-15.050.000.00-10.90-7.07
Sale Or Maturity of Investments0.000.009.419.030.000.0015.468.77
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.006.35-6.020.000.004.561.70
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock10.4918.562.9020.240.000.006.273.86
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock10.4918.562.9020.240.000.006.273.86
Proceedsfrom Stock Options10.4418.512.5820.190.000.006.273.86
Issuance or Reduction of Debt, Net0.000.000.000.232.252.000.000.00
Change in Long Term Debt0.000.000.000.000.002.000.000.00
Issuance of Long Term Debt0.000.000.000.000.002.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.050.030.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities10.4918.562.9020.472.252.056.293.86
Net Change in Cash1.439.33-5.977.24-3.23-4.785.491.14
Free Cash Flow-9.07-9.23-15.22-7.21-5.48-6.83-5.37-4.42
Preferred Dividends (Cash Flow)-0.000.00-----
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments8.499.5310.2411.927.072.22
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.011.700.660.791.120.82
Total Current Assets9.5011.2310.9112.718.193.04
Net Property, Plant & Equipment0.070.080.090.100.100.11
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets---0.03--
Other Assets0.710.211.301.301.301.30
Total Assets10.2911.5212.2914.139.594.44
Short Term Debt Incl. Current Port. of LT Debt0.030.030.030.030.030.03
Accounts Payable1.651.010.640.581.681.19
Other Current Liabilities0.901.201.571.530.560.94
Total Current Liabilities2.582.252.242.152.282.16
Long Term Debt0.050.060.070.080.090.10
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.03--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities2.632.312.312.252.362.26
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity7.659.219.9811.887.222.18
Total Shareholders Equity7.659.219.9811.887.222.18
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity7.659.219.9811.887.222.18
Total Liabilities & Stockholders Equity10.2911.5212.2914.139.594.44
Book Value Per Share2.323.133.934.703.682.09
Tangible Book Value Per Share2.323.133.934.703.682.09
Full-Time Employees---16--
Price to Book Ratio1.341.041.252.181.653.68
Return on Assets-121.14-139.85-139.27-122.75-158.62-191.80
Return on Equity-161.84-195.88-207.37-156.90-234.70-334.12
Return on Invested Capital-46.00-32.42-24.22-25.52-36.54-111.32
Quick Ratio3.685.004.865.923.601.40
Current Ratio3.685.004.865.923.601.40

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-3.54-3.01-2.43-3.05-2.67-2.54
Depreciation0.010.010.010.010.010.01
Other Funds (Non Cash)0.520.390.390.450.470.64
Funds from Operations-3.02-2.61-2.04-2.59-2.19-1.89
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.520.270.210.19-0.19-0.57
Cash from Operating Activities-2.50-2.34-1.83-2.40-2.39-2.46
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.471.620.157.257.243.74
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.471.620.157.257.243.74
Proceedsfrom Stock Options1.471.620.157.207.243.74
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.471.620.157.257.243.74
Net Change in Cash-1.03-0.72-1.684.854.851.29
Free Cash Flow-2.50-2.34-1.83-2.40-2.39-2.46

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.39%0.1M3.2M25.09K
2026-10-152.80%0.1M3.1M26.51K
2026-09-301.22%0.0M3.1M30.74K
2026-09-151.00%0.0M3.1M40.87K
2026-08-311.56%0.0M3.1M44.27K
2026-08-142.63%0.1M3.1M40.63K
2026-07-312.66%0.1M2.6M40.83K
2026-07-156.33%0.2M2.6M43.14K
2026-06-304.92%0.1M2.6M37.80K
2026-06-152.26%0.1M2.6M28.78K
2026-05-292.93%0.1M2.6M28.25K
2026-05-153.05%0.1M2.5M41.61K
2026-04-302.95%0.1M2.5M47.17K
2026-04-152.84%0.1M2.3M50.18K
2026-03-312.60%0.1M2.4M53.09K
2026-03-132.25%0.1M2.3M61.02K
2026-02-273.08%0.1M2.3M87.47K
2026-02-131.84%0.0M2.3M81.39K
2026-01-302.09%0.0M2.2M262.65K
2026-01-152.66%0.1M2.2M1.18M

Option chain

expiry 2026-11-13
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-058-KCurrent report2026-11-05SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-08S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-06-168-KCurrent report2026-06-16SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-30ARSAnnual report to security holders. 2025-12-31SEC
2026-04-30DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-30SEC
2026-03-304Statement of changes in beneficial ownership of securities2026-03-26SEC
2026-03-278-KCurrent report2026-03-27SEC
2026-03-2710-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-238-KCurrent report2026-03-23SEC
2026-03-23424B5SEC
2026-03-068-KCurrent report2026-03-05SEC
2026-03-058-KCurrent report2026-03-05SEC
2026-02-138-KCurrent report2026-02-13SEC
2026-01-23S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-01-054Statement of changes in beneficial ownership of securities2025-12-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Kingsbury Capital Investment Advisors LLC21.64%
VANGUARD CAPITAL MANAGEMENT LLC0.98%
SAPIENT CAPITAL LLC0.96%
NANO CAP NEW MILLENNIUM GROWTH FUND L P0.92%
Rothschild Wealth LLC0.89%
GEODE CAPITAL MANAGEMENT, LLC0.68%
FNY Investment Advisers, LLC0.48%
Mesirow Financial Investment Management, Inc.0.43%
VANGUARD FIDUCIARY TRUST CO0.34%
STATE STREET CORP0.33%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.98%
Fidelity Extended Market Index Fund0.36%
Fidelity Series Total Market Index Fund0.10%
Fidelity Total Market Index Fund0.09%
Fidelity Nasdaq Composite Index Fund0.01%

OakChart. INTS. Cached 15 minutes. Terms

Some panels did not load: ratings, insider.